Toutes les études
RecrutementNAINTERVENTIONNEL

Algorithm-based Management to Reduce the Recurrence of GI Bleeding and Severe Epistaxis in Von Willebrand Disease

The WILL MANAGE study aims to find better ways to prevent reoccurring bleeding in people who have Von Willebrand Disease (VWD). VWD is a genetic condition that affects how your blood clots, leading to more bleeding than usual. This study focuses on reducing serious stomach bleeding or severe nosebleeds through two different ways of managing the condition: a new, specially designed management plan and the care usually given. Researchers want to see if the new approach can lower the number of times these serious bleeds happen again. It's a randomised study, meaning participants will be assigned to one of the two groups by chance.

En un coup d'œil

Statut
Recrutement
Phase
NA
Sponsor
Hôpital Universitaire, Lille
Objectif d'inscription
66
Démarrer
10 mars 2026
Achèvement estimé
01 Mar 2032

De quoi parle cette étude ?

Von Willebrand Disease (VWD) is a common inherited bleeding disorder, meaning it's passed down through families. People with VWD don't have enough of a protein called von Willebrand factor, or it doesn't work properly. This protein plays a key role in helping your blood clot, so if it's faulty, you might experience more bleeding than usual. This could include things like heavy periods, easy bruising, or prolonged bleeding from cuts.

Sometimes, VWD can lead to more serious bleeding, such as bleeding in the stomach or gut (gastrointestinal bleeding) or very severe nosebleeds. These can be difficult to manage and can significantly impact a person's life. Doctors are always looking for ways to better prevent these serious bleeding episodes from happening again.

This study, called WILL MANAGE, is designed to compare two different ways of managing VWD in people who have had these serious bleeding problems. One approach is the 'standard of care,' which is the usual treatment doctors currently give. The other is a new, structured management plan developed by doctors and specialists. The goal is to see if this new approach can help reduce how often these serious stomach bleeds or nosebleeds happen again, ultimately improving the health and quality of life for people with VWD.

Points clés

  • This study aims to make serious bleeding less common in VWD.
  • It compares a new management plan to current standard care.
  • Focus is on stomach/gut bleeding and severe nosebleeds.
  • Participation involves being randomly assigned to one of two care groups.
  • You must have an inherited form of VWD and be aged 18+.
  • You can stop participating at any time if you wish.

Qui peut être éligible ?

To join this study, you need to be an adult aged 18 or over. You must have been diagnosed with Von Willebrand Disease that you were born with, not a form that developed later in life. A key part of joining is having experienced certain types of bleeding: either bleeding in your stomach or gut (which could be obvious, like vomiting blood, or less obvious, causing anaemia), or very severe nosebleeds that required blood transfusions or special treatments.

You also need to be part of a social security scheme, like the NHS, and be able to give your full permission to take part by signing a consent form.

However, there are reasons you might not be able to join. These include if your VWD developed later in life, if you have certain reactions to VWF treatments, some medical conditions like severe liver disease or cancer treatment, if you are pregnant or breastfeeding, or if you are unable to understand and give consent.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Avez-vous 18 ans ou plus ?
  2. Do you have Von Willebrand Disease that you were born with?
  3. Have you had serious stomach/gut bleeding or very severe nosebleeds?
  4. Are you able to give your informed consent to join the study?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

The study involves following one of two management plans for your Von Willebrand Disease. You'll be randomly assigned to either the new, special management plan or the standard care plan. This means you won't get to choose which plan you are on, and neither will your doctor in the study. You will have regular contact with the study team, who will monitor your health and any bleeding episodes you experience. This could involve clinic visits and assessments to track your progress. The total duration of your participation in the study will be explained by the study team, including how long you will be on your assigned management plan and any follow-up checks. Full details will be provided before you agree to take part.

Risques et avantages potentiels

Taking part in a study like this always has potential benefits and risks. A potential benefit is that you might receive careful, expert management of your VWD, and if the new management plan is more effective, you could experience fewer serious bleeding episodes. However, there's also the chance that the new approach might not work better than standard care. As with any medical care, there could be side effects or inconveniences from treatments or assessments, but the study team will monitor you closely. It's very important to remember that you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (17)

  • CHU Lille
    Code postal vérifié
    Lille, France· Pas encore en recrutement
  • CHU Tours
    Code postal vérifié
    Tours, France· Pas encore en recrutement
  • CHU Amiens
    Code postal vérifié
    Amiens, France· Pas encore en recrutement
  • CHRU Brest
    Code postal vérifié
    Brest, France· Pas encore en recrutement
  • Hôpital cardiologique Louis Pradel
    Code postal vérifié
    Bron, France· Pas encore en recrutement
  • CHU Caen
    Code postal vérifié
    Caen, France· Pas encore en recrutement
  • CH Chambery
    Code postal vérifié
    Chambéry, France· Pas encore en recrutement
  • CHU Clermont-Ferrand
    Code postal vérifié
    Clermont-Ferrand, France· Pas encore en recrutement
  • CHU Dijon
    Code postal vérifié
    Dijon, France· Pas encore en recrutement
  • AP-HP Hôpital Kremlin Bicetre
    Code postal vérifié
    Le Kremlin-Bicêtre, France· Pas encore en recrutement
  • AP-HM Hôpital Timone
    Code postal vérifié
    Marseille, France· Pas encore en recrutement
  • CHU Montpellier
    Code postal vérifié
    Montpellier, France· Recrutement

Questions fréquentes

What is Von Willebrand Disease?

It's a common inherited blood disorder where your blood doesn't clot as well as it should, leading to more bleeding.

What kind of bleeding is this study interested in?

It focuses on serious bleeding in the stomach or gut, or very severe nosebleeds that have happened again.

Will I get to choose my treatment in the study?

No, you'll be randomly assigned to either the new management plan or the standard care plan, like drawing lots.

Combien de temps vais-je participer à l'étude ?

The study team will tell you the exact duration, including treatments and follow-up, before you make a decision.

Puis-je quitter l'étude si je change d'avis ?

Yes, you can leave the study at any time, and it won't affect the medical care you usually receive.

Comment en savoir plus

Marie Caillierez

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "Algorithm-based Management to Reduce the Recurrence of GI Bl… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.